Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025)

Hepatology

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol

Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, Midiri F, Mantovani A, Targher G, Krag A, Rinella ME, Cammà C, Petta S

doi: 10.1016/S2468-1253(25)00188-8

Helicobacter Pylori

Effects of Helicobacter pylori Eradication on the Risk and Clinical Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Helicobacter

Li X, Tao Y, Li H, Mai L, He X, Yan J, Yang X

doi: 10.1111/hel.70092

Hepatology

Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis

BMC Gastroenterol

Zou J, Tian F, Cui S, Hou J, Li Z, Wei Y, Cui H, Li Y, Zhou S, He Z, Ma X

doi: 10.1186/s12876-025-04535-1

Hepatology

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

J Gastroenterol Hepatol

Hsieh ML, Su TH, Lin YC, Chen YY, Tung CF, Huang LS, Wu CH, Peng YC, Hsieh VC

doi: 10.1111/jgh.70259

Hepatology

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Lancet Gastroenterol Hepatol

Lazarus JV, Agirre-Garrido L, White TM, Arora AK, Manolas MI, Diaz LA, Arab JP, Zelber-Sagi S, Alkhouri N, Spearman CW, Schattenberg JM, Kondili LA, Carrieri P, Lofton HF, Jaisinghani P, Kumar S, Duseja A, El-Kassas M, Takahasi H, Shawcross DL, Stine JG, Villota-Rivas M, Miralles-Sanchez JE, Pannain S, Brennan PN, MASLD/MASH Collaborators

doi: 10.1016/S2468-1253(25)00300-0

HepatitisHepatology

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Chang YP, Chen YC, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH, Liu CH

doi: 10.1136/gutjnl-2025-337275

Hepatology

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease

Clin Gastroenterol Hepatol

Younossi ZM, Kalligeros M, Wong VW, Al-Naamani KM, Tacke F, Tsochatzis E, Crespo J, El-Kassas M, Bril F, Arrese M, Caussy C, Spearman CW, Gastaldelli A, Pessoa MG, Gadano A, Shubrook JH, Duseja A, Eguchi Y, Chan WK, Fan JG, Holleboom AG, Yu ML, Kim J, Kawaguchi T, Villela-Nogueira C, Oliveria CP, Pik-Shan Kong A, Lam B, Giles H, Betel M, Ong J, Burra P, Yilmaz Y, Pearlman B, Buti M, Papatheodoridis G, Abreu ES, Abdelmalek M, Alkhouri N, Nader F, Stepanova M, Racila A, Paik J, Wajcman DI, Grinshpan LS, Roberts SK, Alqahtani SA, Zelber-Sagi S, Castera L, Henry L

doi: 10.1016/j.cgh.2026.03.030

Further Publications

Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Gastroenterology

Kanwal F, Bril F, Wai-Sun Wong V, Adams LA, Pfotenhauer K, Skolnik N, Wright EE Jr, Eckel RH, Noureddin M, Loomba R, Allen AM, Bansal MB, Godwin KM, El-Serag HB, Shubrook JH

doi: 10.1053/j.gastro.2026.01.047

Gastrointestinal CancerHepatology

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement

Gut

Wu CT, Targher G, Byrne CD, Younossi ZM, Armstrong MJ, Luu HN, Lesmana CRA, Rustgi VK, Thomas JA, Okabayashi K, Lee JWJ, El-Serag HB, Kim W, Zhang HJ, Lonardo A, Souza M, George ES, Yang W, Yilmaz Y, Papatheodoridis G, Sookoian S, Romero-Gómez M, Sebastiani G, Schattenberg JM, El-Kassas M, Chan WK, Ocama P, Lupșor-Platon M, Perera N, Alswat K, Méndez-Sánchez N, Wong VW, Chai J, Tilg H, Sung JJ, Zheng MH

doi: 10.1136/gutjnl-2025-337374

Related content

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Effects of Helicobacter pylori Eradication on the Risk and Clinical Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease

Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement